TECH OFFER

Novel Drug for Cancer Diagnostics and Photodynamic Treatment

KEY INFORMATION

TECHNOLOGY CATEGORY:
Healthcare - Diagnostics
Healthcare - Pharmaceuticals & Therapeutics
TECHNOLOGY READINESS LEVEL (TRL):
LOCATION:
Hong Kong
ID NUMBER:
TO166838

TECHNOLOGY OVERVIEW

Photodynamic therapy (PDT) is well-known in treating cancer where cancer cells can be safely radiated.  This is especially true for cancers like skin cancer, prostate cancer and bladder cancer. However, only a few photosensitizer drugs (PD) for PDT such as Photofrin® Porfimer sodium (Photofrin®), Temoporfin (Foscan®), Motexafin lutetium, Palladium bacteriopheophorbide, Purlytin®, Verteporfin (Visudyne®), Talaporfin (Laserphyrin®) are approved by FDA or under-clinical trials.

Statistics shows that Australia has the highest prevalence of skin cancer and is estimated that 37-55% Australian are affected in the global market study on PDT. The growing prevalence of skin cancer in other countries like the US and the UK is fast and therefore it drives the revenue growth of the PDT market. In light of large demand in PDs and unmet need for PD’s improvement in terms of cancer cell specificity, depth of light penetration and safety, we have developed a drug which is used for two-photon absorption photodynamic therapy.

The drug is porphyrin-lanthanide complexes with specific functional groups which are conjugated with carefully chosen peptides so as to increase cancer cells specificity. In-house studies showed that the drug is able to significantly kill cancer cells without attacking normal cells and can give responsive emission for diagnostics.   We have a portfolio of granted and pending patents in the US, Europe, Taiwan, China and Hong Kong. Currently, we are seeking partners to collaborate and bring this drug to the next stage of clinical trials.

TECHNOLOGY FEATURES & SPECIFICATIONS

The drug is safe as it is used at a lower light irradiation (i.e. 10 J/cm2 vs standard dose of 50 J/cm2) and can be used with magnetic resonance imaging (MRI) for early-stage disease diagnosis. It is less invasive when comparing to positron emission tomography (PET) and X-ray computer tomography. With the MRI, the drug provides high-resolution images for accurate diagnosis of cancer.  Besides, it will only attack cancer cells instead of normal cells. Therefore, it will not induce adverse effects in patients during and after the treatment.

POTENTIAL APPLICATIONS

Our drug can be used for early-stage cancer diagnosis and killing cancer cells in-situ.

Benefits

Benefits of our drug include:

  • Reliable, minimally invasive clinical treatment for cancer patients
  • Cancer cell-specific and in-situ monitoring
  • Safe
RELATED TECH OFFERS
Therapeutic Inhibitor for Epstein-Barr Virus (EBV)-associated Cancers
Cancer Catcher - Early Detection of Circulating Tumour Cells
Potent Anti-bacterial Plant Oil for Skin Health and Ailment
Melanin Derived From Black Soldier Flies
Non-Invasive, Non-Toxic Encapsulation Technology to Prolong Effects of Leave-on Products
Novel Anti-microbial Agent for Preventing Dental Caries
Non-invasive Alzheimer’s Disease Diagnostic Kit
Growth Factor-free Proliferation & Differentiation of Stem Cell
A modified Chinese Medicine formulation for treating Alzheimer's disease
Plant-Harvested Biopolymer for Postsurgical Adhesion Barrier Gel and Film Application